Basal cell carcinoma - Basale Sel Carcinoma https://en.wikipedia.org/wiki/Basal-cell_carcinoma
Basal cell carcinoma is the most common type of skin cancer. It often appears as a painless, raised, hard area of skin. The lesion may be shiny and may have small blood vessels running over it. It may also present as a raised area with ulceration. Basal cell carcinoma grows slowly and can damage the surrounding tissue, but it is unlikely to metastasize or cause death.

Risk factors include exposure to ultraviolet light, radiation therapy, long‑term exposure to arsenic and poor immune‑system function (e.g., organ transplantation). Exposure to UV light during childhood is particularly harmful.

After diagnosis by biopsy, treatment is typically surgical removal. This can be simple excision if the cancer is small; if the cancer is larger, Mohs surgery is generally recommended.

Basal cell carcinoma accounts for at least 32% of all cancers globally. Of skin cancers other than melanoma, about 80% are basal‑cell cancers. In the United States, about 35% of white males and 25% of white females are affected by basal cell carcinoma at some point in their lives.

○ Diagnose en behanneling
#Dermoscopy
#Skin biopsy
#Mohs surgery
Mear ynformaasje ― Frysk
References Basal cell carcinoma: pathogenesis, epidemiology, clinical features, diagnosis, histopathology, and management 26029015 
NIH
Basal cell carcinoma (BCC) is the most common type of skin cancer. Exposure to sunlight is the most important risk factor. Most, if not all, BCCs show overactive Hedgehog signaling in the molecular analysis. Various treatments are available and chosen based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
Basal cell carcinoma (BCC) is the most common malignancy. Exposure to sunlight is the most important risk factor. Most, if not all, cases of BCC demonstrate overactive Hedgehog signaling. A variety of treatment modalities exist and are selected based on recurrence risk, importance of tissue preservation, patient preference, and extent of disease.
 Update in the Management of Basal Cell Carcinoma 32346750 
NIH
Basal cell carcinoma binne it meast foarkommende type hûdkanker yn folwoeksenen mei ljochte hûd fan 50 jier en âlder. Harren oantal nimt wrâldwiid ta, benammen troch bleatstelling oan sinneljocht. Bepaalde genetyske omstannichheden kinne minsken gefoelich meitsje foar it ûntwikkeljen fan dizze kankers op in jongere leeftyd. Basal cell carcinoma fariearje yn earnst, fariearjend fan maklik te behanneljen oerflakkige as nodulêre lesions oant wiidweidigere dy't diskusje nedich binne yn spesjalisearre medyske teams. Prognoaze hinget ôf fan 'e kâns dat kanker weromkomt of har fermogen om tichtby weefsel te beskeadigjen. Surgery is de standert behanneling foar de measte gefallen, garandearret krekte ferwidering en lege kânsen op weromkomst. Minder invasive metoaden kinne oerflakkige lesions effektyf behannelje.
Basal cell carcinomas are the most frequent skin cancers in the fair-skinned adult population over 50 years of age. Their incidence is increasing throughout the world. Ultraviolet (UV) exposure is the major carcinogenic factor. Some genodermatosis can predispose to formation of basal cell carcinomas at an earlier age. Basal cell carcinomas are heterogeneous, from superficial or nodular lesions of good prognosis to very extensive difficult-to-treat lesions that must be discussed in multidisciplinary committees. The prognosis is linked to the risk of recurrence of basal cell carcinoma or its local destructive capacity. The standard treatment for most basal cell carcinomas is surgery, as it allows excision margin control and shows a low risk of recurrence. Superficial lesions can be treated by non-surgical methods with significant efficacy.
 European consensus-based interdisciplinary guideline for diagnosis and treatment of basal cell carcinoma-update 2023 37604067
De primêre behanneling foar BCC is sjirurgy. Foar hege risiko of weromkommende BCC, benammen yn krityske gebieten, wurdt mikrografysk kontroleare sjirurgy oanrikkemandearre. Pasjinten mei leech-risiko oerflakkige BCC kinne topike behannelingen as destruktive metoaden beskôgje. Fotodynamyske terapy wurket goed foar oerflakkige en lege risiko nodulêre BCC's. Foar lokaal avansearre of metastatyske BCC wurden Hedgehog-ynhibitoren (vismodegib, sonidegib) oanrikkemandearre. As der sykteprogressie of yntolerânsje is foar Hedgehog-ynhibitoren, kin immunotherapy mei anti-PD1 antibody (cemiplimab) wurde beskôge. Radiotherapy is in goede opsje foar pasjinten dy't gjin sjirurgy kinne hawwe, benammen âldere pasjinten. Elektrochemotherapy kin beskôge wurde as sjirurgy of radiotherapy gjin opsje is.
The primary treatment for BCC is surgery. For high-risk or recurring BCC, especially in critical areas, micrographically controlled surgery is recommended. Patients with low-risk superficial BCC might consider topical treatments or destructive methods. Photodynamic therapy works well for superficial and low-risk nodular BCCs. For locally advanced or metastatic BCC, Hedgehog inhibitors (vismodegib, sonidegib) are recommended. If there's disease progression or intolerance to Hedgehog inhibitors, immunotherapy with anti-PD1 antibody (cemiplimab) can be considered. Radiotherapy is a good option for patients who can't have surgery, especially older patients. Electrochemotherapy could be considered if surgery or radiotherapy isn't an option.